5-甲基-2-硒吩羰基氯化物 | 30468-07-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硒吩
• 中文名称: 5-甲基-2-硒吩羰基氯化物
• 英文名称: 5-methyl-selenophene-2-carbonyl chloride
• 英文别名: 5-Methylselenophen-2-carbonylchlorid；5-Methylselenophene-2-carbonyl chloride
• CAS: 30468-07-6
• 化学式: C₆H₅ClOSe
• 分子量: 207.518
• InChiKey: STCLJEYGLUQGSS-UHFFFAOYSA-N

物化性质

• 沸点：
  249.6±20.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.43
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2916190090

反应信息

• 作为反应物：
  描述：

  5-甲基-2-硒吩羰基氯化物 在 三乙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 反应 64.5h， 生成 6-methoxy-2-(5-methylselenophen-2-yl)quinolin-4(1H)-one
  参考文献：
  名称：

  Synthesis and in vitro anticancer activity of 6,7-methylenedioxy (or 5-hydroxy-6-methoxy)-2-(substituted selenophenyl)quinolin-4-one analogs

  摘要：

  6,7-Methylenedioxy (or 5-hydroxy-6-methoxy)-2-(substituted selenophenyl)quinolin-4-ones and their isosteric compounds were synthesized and evaluated for anticancer activity. Structure activity relationships (SAR) of these compounds were established. Among all tested compounds, 6,7-methylenedioxy-2-(5-methylselenophen-2-yl)quinolin-4-one (4d) was found to be the most promising anticancer agent. In screening against NCI's 60 human tumor cell line panel, 4d exhibited highly selective and potent inhibitory activity against MDA-MB-435 melanoma. Furthermore, the results of COMPARE analysis suggested that 4d is an antimitotic agent with a different mechanism of action from the conventional antimitotic agents, such as colchicine, vinca alkaloids and paclitaxel. Therefore, 4d was identified as a new lead compound that merits further optimization. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.10.017
• 作为产物：
  描述：

  5-methylselenophene-2-carboxylic acid 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 5-甲基-2-硒吩羰基氯化物
  参考文献：
  名称：

  新型抗癌药1-苄基-3-（5-羟甲基-2-呋喃基）硒代[3,2- c ]吡唑衍生物的合成

  摘要：

  作为我们继续寻找YC-1类似物中潜在抗癌药物候选物的一部分，合成了1，3-双取代的硒代[3,2- c ]吡唑衍生物，并评估了其对NCI-H226非小细胞肺癌和非小细胞肺癌的细胞毒性。 A-498肾癌细胞系。在3-（5-羟甲基-2-呋喃基）衍生物（观察到的细胞毒性显著2，33，36和37）。其中，发现化合物2具有最有效的活性。化合物2的作用方式似乎与NCI标准数据库中列出的175种抗癌药不同，类似于YC-1。因此，我们建议化合物2 应进一步发展为治疗非小细胞肺癌和肾癌的新药候选药物。

  DOI：

  10.1016/j.ejmech.2009.12.039

文献信息

• Synthesis of 1-benzyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole derivatives as new anticancer agents
  作者：Li-Chen Chou、Li-Jiau Huang、Mei-Hua Hsu、Mei-Chi Fang、Jai-Sing Yang、Shi-Hong Zhuang、Hui-Yi Lin、Fang-Yu Lee、Che-Ming Teng、Sheng-Chu Kuo

  DOI：10.1016/j.ejmech.2009.12.039

  日期：2010.4

  As part of our continuing search for potential anticancer drug candidates among YC-1 analogs, 1, 3-disubstituted selenolo[3,2-c]pyrazole derivatives were synthesized and evaluated for their cytotoxicity against NCI-H226 non-small cell lung cancer and A-498 renal cancer cell lines. Significant cytotoxicity was observed in 3-(5-hydroxymethyl-2-furyl) derivatives (2, 33, 36 and 37). Among them, compound

  作为我们继续寻找YC-1类似物中潜在抗癌药物候选物的一部分，合成了1，3-双取代的硒代[3,2- c ]吡唑衍生物，并评估了其对NCI-H226非小细胞肺癌和非小细胞肺癌的细胞毒性。 A-498肾癌细胞系。在3-（5-羟甲基-2-呋喃基）衍生物（观察到的细胞毒性显著2，33，36和37）。其中，发现化合物2具有最有效的活性。化合物2的作用方式似乎与NCI标准数据库中列出的175种抗癌药不同，类似于YC-1。因此，我们建议化合物2 应进一步发展为治疗非小细胞肺癌和肾癌的新药候选药物。
• Shulezhko,A.A., Journal of Organic Chemistry USSR (English Translation), 1970, vol. 6, p. 2129 - 2132
  作者：Shulezhko,A.A.

  DOI：——

  日期：——
• Synthesis and in vitro anticancer activity of 6,7-methylenedioxy (or 5-hydroxy-6-methoxy)-2-(substituted selenophenyl)quinolin-4-one analogs
  作者：Chien-Ting Chen、Mei-Hua Hsu、Yung-Yi Cheng、Chin-Yu Liu、Li-Chen Chou、Li-Jiau Huang、Tian-Shung Wu、Xiaoming Yang、Kuo-Hsiung Lee、Sheng-Chu Kuo

  DOI：10.1016/j.ejmech.2011.10.017

  日期：2011.12

  6,7-Methylenedioxy (or 5-hydroxy-6-methoxy)-2-(substituted selenophenyl)quinolin-4-ones and their isosteric compounds were synthesized and evaluated for anticancer activity. Structure activity relationships (SAR) of these compounds were established. Among all tested compounds, 6,7-methylenedioxy-2-(5-methylselenophen-2-yl)quinolin-4-one (4d) was found to be the most promising anticancer agent. In screening against NCI's 60 human tumor cell line panel, 4d exhibited highly selective and potent inhibitory activity against MDA-MB-435 melanoma. Furthermore, the results of COMPARE analysis suggested that 4d is an antimitotic agent with a different mechanism of action from the conventional antimitotic agents, such as colchicine, vinca alkaloids and paclitaxel. Therefore, 4d was identified as a new lead compound that merits further optimization. (C) 2011 Elsevier Masson SAS. All rights reserved.